Menarini | Invigorating Lives In Asia-Pacific

Invigorating Lives
In Asia-Pacific

Menarini is the largest Italian multinational biopharmaceutical company with nearly 17,000 employees worldwide and presence in more than 100 countries, including Europe, Africa, Middle East, Asia-Pacific, Central and Latin America.

Founded in 1886, Menarini markets products in key therapeutic fields including respiratory, cardiovascular, gastroenterology, metabolism, antibiotics, diabetes, anti-inflammatories and analgesics.

Featured Brand Launch

Priligy® is the first and only approved prescription product specifically approved for the treatment of premature ejaculation (PE), a condition that affects up to 30% of men around the world. In five clinical programs, Priligy® was demonstrated to significantly improve all measures of PE such as personal distress related to ejaculation and satisfaction with sexual intercourse. Priligy® is clinically proven to be safe and generally well tolerated.

Invida Rebrands to Menarini

Invida Holdings announced its name change to A. Menarini Asia-Pacific Holdings Pte. Ltd. on 6 December 2012. The brand transformation reflects its alignment with parent, Menarini Group, and allows for the promotion of a single, unified brand in the global marketplace. “We are proud to build on Menarini’s more than 125 years of history, bringing Menarini’s products and expertise into our already established operations in Asia-Pacific,” said John A. Graham, CEO of Menarini Asia-Pacific.

Welcome

Menarini Asia-Pacific is a leading biopharmaceutical company, focused on delivering differentiated ethical and consumer healthcare brands across the region. With over 3,300 professionals in 13 major markets, Menarini Asia-Pacific operates across the entire commercial value chain, from regulatory approval and product launch to lifecycle management and offers an unparalleled customer experience to partners wanting to tap into the Asia-Pacific growth story.

Our Brands

Corporate Video

Latest Updates

Premature ejaculation diminishes sexual satisfaction for many couples

SINGAPORE, 21 March 2013 – At the 28th Annual European Association of Urology (EAU) Congress in Milan, Europe’s largest urology event with over 100 countries participating and over 14,000 visitors, healthcare professionals were urged to consider the impact of premature ejaculation (PE) on both men and their partners. During a symposium at the EAU Congress, sponsored by Menarini Group, entitled…

Menarini Asia-Pacific Highlights Social Consequences of Premature Ejaculation at 10th International Congress of Andrology

Education efforts help de-stigmatize one of the most common male sexual issues to impact couples

SINGAPORE, 28 February 2013 – Menarini Asia-Pacific, as part of leading international biopharmaceutical company, Menarini Group, participated at this year’s International…

Invida changes name to Menarini Asia-Pacific

Name change reflects new status as a member of the Menarini Group, the largest Italian biopharmaceutical company
Access to full pharmaceutical capabilities of Menarini Group to expand footprint within Asia-Pacific
Wins ‘Best Italian Multinational Corporation in Singapore 2012’ at 4th Italian Chamber of Commerce in Singapore Business Awards